Waters plans to combine with the Biosciences & Diagnostic Solutions business of BD (Becton, Dickinson & Co.), the companies said, in a $17.5 billion deal that would be the year’s largest within life ...

One of the biggest barriers to the adoption of any new biotechnology tool is validation and regulatory clarity.

Nutcracker Therapeutics and Elegen see their mission as delivering scalable and low-cost RNA manufacturing for individualized therapies.

Life science researchers have developed tools that scan millions of papers weekly for signs of fraud, but detection remains challenging.